Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 69 Debt-to-Equity is 0.12 as of Dec. 2025, which is at its 10-year median of 0.12. GuruFocus rates THOXF with a GF Score™ of 69/100 and a GF Value™ of $0.16. The stock has 4 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Bioporto AS ranks better than 69.95% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bioporto AS's Debt-to-Equity or its related term are showing as below:
THOXF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.12 Max: 0.28
Current: 0.12
During the past 13 years, the highest Debt-to-Equity Ratio of Bioporto AS was 0.28. The lowest was 0.00. And the median was 0.12.
THOXF's Debt-to-Equity is ranked better than 69.95% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs THOXF: 0.12
Bioporto AS (OTCPK:THOXF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bioporto AS Debt-to-Equity Related Terms
Bioporto AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a Debt-to-Equity of 0.12 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bioporto AS and its competitors. This is near median its historical median of 0.12. According to the industry distribution chart, Bioporto AS ranks #55 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 30.1%.
Is Bioporto AS's Debt-to-Equity too high?
Bioporto AS's current Debt-to-Equity of 0.12 is near median its 10-year median of 0.12. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Bioporto AS's value of 0.12 is 63.6% below this industry median. Based on the distribution chart, Bioporto AS ranks #55 out of 183 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #55 out of 183 companies for Debt-to-Equity. This puts Bioporto AS in the upper half of its industry. The industry median Debt-to-Equity is 0.33. Bioporto AS's value of 0.12 is 63.6% below this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.33, Bioporto AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Debt-to-Equity of 0.12 is 63.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Debt-to-Equity is 0.12, which is near median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Debt-to-Equity of 0.12. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current Debt-to-Equity is 0.12, which is near median its 10-year median of 0.12 and 63.6% below the Medical Diagnostics & Research industry median of 0.33. Bioporto AS's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Debt-to-Equity is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.
Key valuation signals for THOXF:
Debt-to-Equity: 0.12 (near median its 10-year median of 0.12)
GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
Industry Position: 63.6% below the Medical Diagnostics & Research median (#55 of 183)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score
Get the complete analysis for THOXF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
